Absci Corporation (ABSI)
NASDAQ: ABSI
· Real-Time Price · USD
3.02
-0.01 (-0.33%)
At close: May 02, 2025, 3:59 PM
3.06
1.16%
After-hours: May 02, 2025, 05:58 PM EDT
Company Description
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States.
Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process.
Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Absci Corporation
| Country | United States |
| IPO Date | Jul 22, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 156 |
| CEO | Dr. Andreas Busch Ph.D. |
Contact Details
Address: 18105 SE Mill Plain Boulevard Vancouver, Washington United States | |
| Website | https://www.absci.com |
Stock Details
| Ticker Symbol | ABSI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001672688 |
| CUSIP Number | 00091E109 |
| ISIN Number | US00091E1091 |
| Employer ID | 45-3931977 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Karin Wierinck | Chief People Officer |
| Shelby Walker J.D. | Chief Legal Officer |
| Anders Kassow | Head of Intellectual Property |
| Dr. Amaro Taylor-Weiner Ph.D. | Chief AI Officer |
| Dr. Andreas Busch Ph.D. | Chief Innovation Officer & Member of Scientific Advisory Board |
| Dr. Christian Stegmann M.B.A., Ph.D. | Senior Vice President of Drug Creation |
| Dr. Christine Lemke D.V.M., M.B.A., Ph.D. | Senior Vice President of Portfolio & Growth Strategy |
| Melissa Patterson Ph.D. | Chief of Staff |
| Wen Sha | Chief of Staff |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 29, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEFA14A | Filing |
| Apr 28, 2025 | DEF 14A | Filing |
| Apr 28, 2025 | 8-K | Current Report |
| Apr 11, 2025 | 424B3 | Filing |
| Apr 01, 2025 | S-3 | Filing |
| Mar 18, 2025 | S-8 | Filing |
| Mar 18, 2025 | 10-K | Annual Report |
| Mar 18, 2025 | 8-K | Current Report |